The RNA-binding protein CSTF2 regulates BAD to inhibit apoptosis in glioblastoma

被引:6
作者
Xu, Yang [1 ,2 ]
Yuan, Fanen [1 ,2 ]
Sun, Qian [1 ,2 ]
Zhao, Linyao [1 ,2 ]
Hong, Yu [1 ,2 ]
Tong, Shiao [1 ,2 ]
Qi, Yangzhi [1 ]
Ye, Liguo [1 ]
Hu, Ping [1 ]
Ye, Zhang [1 ]
Zhang, Si [1 ,2 ]
Liu, Baohui [1 ]
Chen, Qianxue [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Neurosurg, 238 Jiefang St, Wuhan 430060, Hubei, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan 430060, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
RNA binding protein; CSTF2; Glioblastoma; BAD; Apoptosis; MOLECULAR-MECHANISMS; POLYADENYLATION; CLEAVAGE; TARGET; CANCER; SPECIFICITY; CARCINOMA; PATHOLOGY; PROMOTES;
D O I
10.1016/j.ijbiomac.2022.12.044
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RNA-binding proteins (RBP) regulate several aspects of co-and post-transcriptional gene expression in cancer cells. CSTF2 is involved in the expression of many cellular mRNAs and involved in the symbolscript cleavage and polyadenylation of pre-mRNAs to terminate transcription. However, the role of CSTF2 in human glioblastoma (GBM) and the underlying mechanisms remain unclear. In the present study, CSTF2 was found to be upregulated in GBM, and its high expression predicted poor prognosis. Knockdown CSTF2 induced GBM cell apoptosis both in vitro and in vivo. Specific mechanism studies showed that CSTF2 unstabilized the mRNA of the BAD protein by shortening its 3' UTR. Additionally, an increase in the expression level of CSTF2 decreased the expression level of BAD. In conclusion, CSTF2 binds to the mRNA of the BAD protein to shorten its 3'UTR, which negatively affects the BAD mediated apoptosis and promotes GBM cell survival.
引用
收藏
页码:915 / 926
页数:12
相关论文
共 41 条
[1]   Glioblastoma: pathology, molecular mechanisms and markers [J].
Aldape, Kenneth ;
Zadeh, Gelareh ;
Mansouri, Sheila ;
Reifenberger, Guido ;
von Deimling, Andreas .
ACTA NEUROPATHOLOGICA, 2015, 129 (06) :829-848
[2]   Characterization of a Cleavage Stimulation Factor, 3′ pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer [J].
Aragaki, Masato ;
Takahashi, Koji ;
Akiyama, Hirohiko ;
Tsuchiya, Eiju ;
Kondo, Satoshi ;
Nakamura, Yusuke ;
Daigo, Yataro .
CLINICAL CANCER RESEARCH, 2011, 17 (18) :5889-5900
[3]  
Billard C, 2013, CURR CANCER DRUG TAR, V13, P1
[4]   GlioVis data portal for visualization and analysis of brain tumor expression datasets [J].
Bowman, Robert L. ;
Wang, Qianghu ;
Carro, Angel ;
Verhaak, Roel G. W. ;
Squatrito, Massimo .
NEURO-ONCOLOGY, 2017, 19 (01) :139-141
[5]   Bad phosphorylation as a target of inhibition in oncology [J].
Bui, Ngoc-Linh-Chi ;
Pandey, Vijay ;
Zhu, Tao ;
Ma, Lan ;
Basappa ;
Lobie, Peter E. .
CANCER LETTERS, 2018, 415 :177-186
[6]   CSTF2-Induced Shortening of the RAC1 3′UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder [J].
Chen, Xin ;
Zhang, Jia-Xing ;
Luo, Jun-Hang ;
Wu, Song ;
Yuan, Gang-Jun ;
Ma, Ning-Fang ;
Feng, Yong ;
Cai, Mu-Yan ;
Chen, Ri-Xin ;
Lu, Jun ;
Jiang, Li-Juan ;
Chen, Jie-Wei ;
Jin, Xiao-Han ;
Liu, Hai-Liang ;
Chen, Wei ;
Guan, Xin-Yuan ;
Kang, Tie-Bang ;
Zhou, Fang-Jian ;
Xie, Dan .
CANCER RESEARCH, 2018, 78 (20) :5848-5862
[7]   Glioblastoma: From Molecular Pathology to Targeted Treatment [J].
Cloughesy, Timothy F. ;
Cavenee, Webster K. ;
Mischel, Paul S. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9, 2014, 9 :1-25
[8]   BAD: undertaker by night, candyman by day [J].
Danial, N. N. .
ONCOGENE, 2008, 27 (Suppl 1) :S53-S70
[9]   BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis [J].
Danial, NN ;
Gramm, CF ;
Scorrano, L ;
Zhang, CY ;
Krauss, S ;
Ranger, AM ;
Datta, SR ;
Greenberg, ME ;
Licklider, LJ ;
Lowell, BB ;
Gygi, SP ;
Korsmeyer, SJ .
NATURE, 2003, 424 (6951) :952-956
[10]   Protein and RNA dynamics play key roles in determining the specific recognition of GU-rich polyadenylation regulatory elements by human Cstf-64 protein [J].
Deka, P ;
Rajan, PK ;
Perez-Canadillas, JM ;
Varani, G .
JOURNAL OF MOLECULAR BIOLOGY, 2005, 347 (04) :719-733